Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
NCT02737306 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
- Lead sponsor
- CytoDyn, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 14, 2017
- Completion date
- September 30, 2021
- Enrollment
- 11 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.